[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-metastases-from-melanoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-metastases-from-melanoma":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100632303",false,"NCT07511933","Novel Ga68-PSMA PET\u002FCT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases","Novel Ga68-PSMA PET\u002FCT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Stereotactic Irradiated Brain Metastases. A Feasibility Study.","Inclusion Criteria:\n\nFor all groups:\n\n* Written informed consent\n* Age ≥ 18 years old\n* WHO PS 0-3\n* Measurable lesion ≥10mm according to RANO BM\n\nFor brain metastases groups:\n\n\\- newly diagnosed brain metastases from either NSCLC (group 1) or melanoma (group 2) or breast cancer (group 7).\n\nFor radiation necrosis groups:\n\n\\- Brain lesion at the location of a formerly brain metastases that has been treated with SRT (\\> 9 months ago), with the definite diagnosis of radiation necrosis at the location of formerly SRT-treated brain metastases of NSCLC (group 3), melanoma (group 4) and\u002F or breast cancer (group 8).\n\nFor diagnostic dilemma groups:\n\n\\- Brain lesion at the location of a formerly brain metastases with a diagnostic dilemma of radiation necrosis and recurrent brain metastases of NSCLC (group 5), melanoma (group 6) and\u002F or breast cancer (group 9).\n\nExclusion Criteria:\n\nFor all groups:\n\n* Known allergy to Ga68-PSMA\n* Epileptic seizure less than 7 days before Ga68-PSMA PET\u002FCT scan\n* Life expectancy less than 3 months\n* Patients with known prostate carcinoma\n* Pregnancy","ALL",{"count":17,"type":18},100,"ESTIMATED","INTERVENTIONAL",[21],"NA","This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET\u002FCT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.",[24,25,26],"Brain Metastases From Non-small Cell Lung Cancer (NSCLC)","Brain Metastases From Melanoma","Brain Metastases From Breast Cancer",[28,29,30,31],"Brain Metastases","Radiation Necrosis","Diagnostic Imaging","Radiation-induced Toxicity","RECRUITING","2026-03-30",{"date":35,"type":36},"2026-04-06","ACTUAL",{"date":38,"type":36},"2019-12-24",{"date":40,"type":18},"2027-07-01",{"name":42,"class":43},"The Netherlands Cancer Institute","OTHER",""]